I am pleased to inform you that the European Medicines Agency’s annual report 2019 is now available on the Agency’s website.
For the first time, the report is available in a digital version. You can navigate through the digital content and explore certain topics in more depth, for example through interviews and short videos. The digital version also includes an interactive timeline of the Agency’s main activities in 2019.
The first part of the report draws attention to some of the Agency’s main initiatives and challenges, including the successful relocation to Amsterdam, the development and finalisation of the ‘regulatory science strategy to 2025’, the recommendations developed by EMA and national competent authorities on big data in medicines regulation and the response to the discovery of nitrosamine impurities in medicines.
The second part is dedicated to key figures, including core statistics that summarise the main outcomes of EMA’s regulatory procedures and activities, as well as trends and changes observed in recent years. More statistical information about EMA can be found in a print-ready version in pdf format that is published alongside the digital annual report.
I would like to take this opportunity to thank you for your contributions to EMA’s work. Your input to our initiatives and projects, your willingness to share views and concerns, and your participation in our activities are invaluable to our mission to protect the health or citizens in the EU.
I hope that you find the annual report informative and helpful. If you have any comments or suggestions on the report, especially on the new digital version, please take this survey. Your responses are completely anonymous and will help us improve future editions of the report.
With kind regards,
European Medicines Agency
Domenico Scarlattilaan 6 | 1083 HS Amsterdam | The Netherlands